Sign In
Buy MRK
$115.49
+0.320 (+0.278%)
At Close: Jun 17, 2026
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck ASCO Curtain Raiser.
Merck & Co., Inc. (MRK) Bank of America Securities 2023 Healthcare Conference Transcript
04:13am, Sunday, 14'th May 2023
Merck & Co., Inc. (NYSE:MRK ) Bank of America Securities 2023 Healthcare Conference Transcript May 10, 2023 11:40 AM ET Company Participants Geoff Meacham - Analyst, Bank of America Securities Carolin
OPKO Health's Future After Merck Deal: Bright Or Uncertain
12:29pm, Thursday, 11'th May 2023
In the first three months of 2023, the company posted $237.6 million in revenue, up 28.2% from the previous quarter. In addition to the Merck deal, OPKO received a $7 million payment from Vifor in Q1
Should You Buy Merck Stock At $120?
07:00am, Tuesday, 09'th May 2023
Although the company posted upbeat Q1 results late last month, we believe MRK stock is fully valued.
2 Top Healthcare Stocks Defying the Bear Market
08:14am, Sunday, 07'th May 2023
Eli Lilly's tirzepatide could be a weight-loss blockbuster. Merck continues to add indications for oncology therapy Keytruda.
5 Conservative And Cheap Dividend Stocks To Invest In - May 2023
09:00am, Saturday, 06'th May 2023
This article is part of our monthly series where we highlight five companies that are large-cap, relatively safe, dividend-paying and are offering large discounts to their historical norms. We go over
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
10:41am, Thursday, 04'th May 2023
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Generate Income With A Cash-Secured Put On Merck Stock
09:37am, Thursday, 04'th May 2023
A trader selling the July 21, 115-strike put could generate around $300 in premium per contract. The post Generate Income With A Cash-Secured Put On Merck Stock appeared first on Investor's Business D
Merck: Marches Forward, One Of The Best Big Pharma Picks Of 2023
11:49pm, Tuesday, 02'nd May 2023
Q1 2023 earnings exceeded expectations, bolstered by blockbuster drugs Keytruda and Gardasil, with a raised FY23 outlook. Keytruda demonstrated 20.5% YoY growth, while Gardasil reported 35% YoY growth
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
01:12pm, Tuesday, 02'nd May 2023
Can-Fite BioPharma Ltd. NYSEAMERICAN: CANF is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction.
V&M Breakouts: Top Long-Term Growth And Dividend Stocks For May 2023
04:51pm, Monday, 01'st May 2023
The May 2022 total return portfolio for 1-year is up +17.09%, and the May 2021 2-year portfolio is up 21.33%, not adjusted for greater than 2%+ dividends. The first May 2020 portfolio had +66.98% 2-ye
Merck (MRK) Beats on Q1 Earnings and Sales, Ups 2023 View
02:25pm, Thursday, 27'th Apr 2023
Merck (MRK) beats Q1 estimates for earnings and sales. It raises its 2023 guidance.
Merck & Co., Inc. (MRK) Q1 2023 Earnings Call Transcript
12:14pm, Thursday, 27'th Apr 2023
Merck & Co., Inc. (MRK) Q1 2023 Earnings Call Transcript.
Merck beats 1Q expectations as Keytruda gains offset Lagevrio decline
12:11pm, Thursday, 27'th Apr 2023
Merck & Co Inc (NYSE:MRK) has reported a decline in first-quarter sales following an anticipated decline in sales of its Lagevrio (molnupiravir) coronavirus (COVID-19) treatment. The drugmaker also
2 of These 3 Stocks Are Lifting the Dow, but 1 Is Holding It Back
09:26am, Thursday, 27'th Apr 2023
The Dow looked poised for a sizable lift on Thursday morning. Merck and Honeywell released solid financial results that helped boost the Dow.
